CRCristina Ripoll

Cristina Ripoll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cristina Ripoll has a total of 509 co-authors. Here are the top co-authors by number of shared publications:

  • Rafael Bañares

    Department of Digestive Diseases, Instituto de Investigación Sanitaria, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, 28007 Madrid, Spain

    36 shared publications
  • Alexander Zipprich

    Internal Medicine IV, Department for Gastroenterology, Hepatology, Interdisciplinary Endoscopy and Infectious Diseases, Jena University Hospital, Germany

    21 shared publications
  • Diego Rincón

    Sección de Hepatología, Servicio de Aparato Digestivo, Hospital Gregorio Marañón, Madrid, Spain

    17 shared publications
  • Alexander Zipprich

    Department of Internal Medicine IV Jena University Hospital Jena Germany

    13 shared publications
  • Magdalena Salcedo

    Medicina–Ap. Digestivo Hospital General Universitario Gregorio Marañón – CIBERehd – IiSGM. Madrid Spain

    8 shared publications
  • Gerardo Clemente

    Medicina–Ap. Digestivo Hospital General Universitario Gregorio Marañón – CIBERehd – IiSGM. Madrid Spain

    7 shared publications

Latest Publications

  • Open Access

    Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI

    by Eva Maria Schleicher, Christian Labenz, Frank Erhard Uschner, Julian Pohl, Moritz Passenberg, Michael Praktiknjo, Marcus Maximilian Mücke, Henrik Karbannek, Nina Böhling, Karsten Große, et al.

    Background and Aims: Volume expansion with albumin is recommended to establish a diagnosis of hepatorenal syndrome–acute kidney injury (HRS‐AKI). The optimal duration of albumin administration is debated and requires balancing the risk of overtreatment with the need for timely diagnosis and treatment. Therefore, this study aimed to compare the impact of different albumin treatment durations on terlipressin response and the prognosis of patients with HRS‐AKI treated with terlipressin and albumin. Methods: This multicenter, retrospective secondary analysis included patients with suspected HRS‐AKI who were treated with terlipressin and albumin at 12 German centers. One hundred forty five patients were available for further analysis. The cohort was dichotomized into patients treated with albumin for < 24 h and for 24–60 h before initiation of terlipressin. Patients were followed for treatment response to terlipressin, need for haemodialysis (HD), survival, or liver transplantation (LT). Results: Median MELD score of the cohort was 25 [IQR 21; 31]. During follow‐up, 59 patients (40.7%) achieved a complete response to treatment with terlipressin, and 96 patients (66.2%) died or received an LT. Response rates to terlipressin therapy did not differ between albumin treatment groups (< 24 h vs. 24–60 h). In multivariable competing risk models, treatment duration of albumin was not associated with any response to terlipressin, considering death and LT as competing events. Of note, albumin treatment duration did not affect HD−/LT‐free survival. Conclusion: Extending albumin treatment beyond 24 h had no impact on treatment response to terlipressin and albumin or HD‐/LT‐free survival in patients with HRS‐AKI. Clinical Trial Number: NCT 06161766

  • Open Access

    Corrigendum to: “A rare vascular puzzle: Portal hypertension and hepatic lesions” [J Hepatol (2026) 84: e59–61]

    by Clemens Wolf, Kathleen Lange, Andreas Stallmach, Andrea Tannapfel, Cristina Ripoll

  • Open Access

    Comparative performance of ReMELD-Na, MELD 3.0 and established scores after TIPS for refractory ascites: A multicenter study

    by Markus Kimmann, Nancy Farouk, Dominik Bettinger, Johannes Chang, Roman Kloeckner, Cristina Ripoll, Felix Piecha, Jassin Rashidi-Alavijeh, Juliana Stadtmann, Ahmad Shikh Mousa, et al.


  • Open Access

    A rare vascular puzzle: Portal hypertension and hepatic lesions

    by Clemens Wolf, Kathleen Lange, Andreas Stallmach, Andrea Tannapfel, Cristina Ripoll


  • Open Access

    Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome–Acute Kidney Injury

    by Frank Erhard Uschner, Eva Maria Schleicher, Moritz Passenberg, Julian Pohl, Michael Praktiknjo, Anna Teresa Volk, Henrik Karbannek, Johannes Chang, Karsten Große, Charlotte Rohrer, et al.


  • Open Access

    Positionspapier für die standardisierte Anwendung von Transjugulärem Intrahepatischem Portosystemischem Shunt (TIPS) bei Erwachsenen

    by Jonel Trebicka, Christian Steib, Alexander Zipprich, Cristina Ripoll, Johannes Kluwe, Michael Schultheiß, Andreas A. Schnitzbauer, Bernhard Meyer, Christian Jansen, Hauke Heinzow, et al.

    Portale Hypertonie ist mit erheblicher Morbidität und Mortalität verbunden. Die Leberzirrhose macht bis zu 90 % der Fälle von portaler Hypertonie aus, während etwa 10 % auf nicht-zirrhotische Faktoren, einschließlich vaskulärer Lebererkrankungen, zurückzuführen sind. Diese Erkrankung kann zu schweren Komplikationen führen, wie der Entwicklung von gastroösophagealen Varizen, die das Risiko von varikösen Blutungen erheblich erhöhen. Weitere häufige Komplikationen der portalen Hypertonie sind Aszites und hepatorenales Syndrom (HRS). Eine transjuguläre intrahepatische portosystemische Shunt (TIPS)-Implantation wird als die effektivste Behandlung zur Bewältigung der portalen Hypertonie angesehen. Studien zeigen, dass die TIPS-Implantation die Überlebensraten bei Patienten mit wiederkehrendem Aszites sowie bei ausgewählten Patienten mit refraktärem Aszites und varikösen Blutungen verbessern kann. Allerdings können periinterventionelle und postinterventionelle Komplikationen die Anwendung von TIPS einschränken. Neueste Entwicklungen bei Geräten, Techniken und prophylaktischen Medikamenten zielen darauf ab, das Risiko von Komplikationen nach dem Eingriff zu minimieren. Dieses interdisziplinäre Positionspapier fasst Empfehlungen und Anleitung zur Patientenwahl, zu Indikationen und Kontraindikationen, zu Techniken sowie zur Nachsorge von Patienten zusammen, die in Deutschland ein TIPS-Verfahren erhalten. Portal hypertension is associated with significant morbidity and mortality. Liver cirrhosis accounts for up to 90 % of portal hypertension cases, while approximately 10 % are due to non-cirrhotic factors, including vascular liver diseases. This condition can lead to various complications, such as the development of gastroesophageal varices, which greatly increase the risk of variceal bleeding. Other common complications of portal hypertension include ascites and hepatorenal syndrome (HRS). The transjugular intrahepatic portosystemic shunt (TIPS) procedure is regarded as the most effective treatment for managing portal hypertension. Research shows that TIPS insertion can improve survival rates for patients with recurrent ascites, as well as for select individuals with refractory ascites and variceal bleeding. However, peri-interventional and post-interventional complications may pose challenges to the use of TIPS. Recent advancements in devices, techniques, and prophylactic medications aim to minimize the risk of complications following this procedure. This interdisciplinary position paper summarizes recommendations and guidance regarding patient selection, indications and contraindications, techniques, and follow-up care for patients undergoing TIPS in Germany. * Teilen die erste oder die letzte Autorschaft. Received: 25 November 2024 Accepted after revision: 08 May 2025 Article published online: 10 November 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany


  • Open Access

    The impact of sarcopenia and frailty on decompensation in compensated cirrhosis: A systematic review

    by Chiara Becchetti, Elton Dajti, Grace L. Su, Christian Labenz, Antonio Colecchia, Sith Siramolpiwat, Yoji Ishizu, Kathleen P. Ismond, Lucian Beer, Rafael Paternostro, et al.

    Background: Sarcopenia and frailty have a negative prognostic impact in patients with decompensated cirrhosis; however, the impact of these conditions on the prognosis of compensated cirrhosis is unknown. We performed a systematic review to assess the effect of sarcopenia and frailty on decompensation in patients with compensated cirrhosis. Methods: We searched PubMed and Embase for English-language studies published up to April 2025. The primary outcome was decompensation and the secondary outcome was mortality. We included studies with available data on patients with compensated cirrhosis. Results: Eight studies reporting data on sarcopenia (n=829 patients) and 4 studies (n=552 patients) assessing frailty were included in this systematic review. The prevalence of sarcopenia varied from 8% to 63%. Computed tomography at the L3 level and liver frailty index were the methods most commonly used to evaluate sarcopenia and frailty, respectively. Sarcopenia in patients compensated at inclusion was associated with an increased risk of decompensation in some studies, but not in all. When selected patients with compensated cirrhosis and no previous decompensation were studied, most studies showed no increased risk for first decompensation within the follow-up (12–61 mo). Two studies out of the 4 reported a higher risk of decompensation and mortality in patients with frailty. Conclusions: We reported that sarcopenia was prevalent in patients with compensated cirrhosis, but, in most studies, did not lead to an independent, increased risk of first decompensation and death. Well-designed, prospective multicenter studies are essential to assess the association between sarcopenia, frailty, and the risk of first decompensation.


  • Akutes Nierenversagen bei Leberzirrhose

    by Cristina Ripoll, Henrik Karbannek

  • Interaction of inflammation and portal hypertension in cirrhosis progression

    by Dalila Costa, Jonel Trebicka, Cristina Ripoll, Richard Moreau, Rajiv Jalan, Thomas Reiberger

    Decompensated cirrhosis describes an advanced clinical stage with clinical complications, such as ascites, variceal bleeding or hepatic encephalopathy, associated with considerable mortality. Portal hypertension is the main risk factor for developing decompensation in patients with compensated cirrhosis, whereas systemic inflammation is the key driving force for organ failure, that is, for acute-on-chronic liver failure in later stages of cirrhosis. As portal hypertension and systemic inflammation coexist in patients with cirrhosis, an improved understanding of their interaction and dynamic role in distinct stages of cirrhosis is an important step forward towards the development of urgently needed therapeutic interventions. Based on emerging evidence from clinical and translational studies, a novel concept of different predominant pathomechanisms of decompensated cirrhosis is presented, which includes portal hypertension-predominant, systemic inflammmation-predominant and mixed portal hypertension-systemic inflammation phenotypes. A comprehensive set of biomarkers and surrogates of portal hypertension and systemic inflammation might assist clinicians in identifying a predominance of one over the other cirrhosis phenotype. As survival rates of patients with decompensated cirrhosis have remained detrimental without liver transplantation over the past decades, future studies should build on this knowledge to develop effective portal hypertension and systemic inflammation-directed therapies for this underserved population.


  • Non-acute decompensation: Ready for clinical practice?

    by Georg Kramer, Thomas Reiberger, Cristina Ripoll